Clinical implications of local renin-angiotensin-aldosterone systems

Current Cardiology Reports

Volumn 5, Issue 4, 2003, Pages 247-248

  Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

CARDIOVASCULAR SYSTEM; CLINICAL RESEARCH; ENDOTHELIUM INJURY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; MITOGENESIS; NOTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR SMOOTH MUSCLE; CARDIOVASCULAR DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0642308375     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-003-0057-5     Document Type: Note

References (13)

1. 1. MA Pfeffer E Braunwald LA Moye 1992 Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial N Engl J Med 327 145 153 10.1056/NEJM199209033271001 Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992, 327:145–153.
2. 2. S Yusuf P Sleight J Pogue 2000 Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation study investigators N Engl J Med 342 145 153 10639539 10.1056/NEJM200001203420301 1:STN:280:DC%2BD3c%2Fpt1emug%3D%3D Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation study investigators. N Engl J Med 2000, 342:145–153.
3. 3. VJ Dzau R Re 1994 Tissue angiotensin systems in cardiovascular medicine: a paradigm shift? Circulation 89 493 498 8281685 1:STN:280:DyaK2c7gvFSmtg%3D%3D Dzau VJ, Re R: Tissue angiotensin systems in cardiovascular medicine: a paradigm shift? Circulation 1994, 89:493–498.
4. 4. VJ Dzau RN Re 1987 Evidence for the existence of rein in the heart Circulation 75 Suppl 1 134 136 Dzau VJ, Re RN: Evidence for the existence of rein in the heart. Circulation 1987, 75 (Suppl 1):134–136.
5. 5. L Barlucchi A Leri DE Dostal 2001 Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure Circ Res 88 298 304 11179197 1:CAS:528:DC%2BD3MXhtlyltbw%3D Barlucchi L, Leri A, Dostal DE, et al.: Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001, 88:298–304.
6. 6. Y Sun J Zhang JQ Zhang 2001 Renin expression at sites of repair in the infarcted rat heart J Mol Cell Cardiol 33 995 1003 11343421 10.1006/jmcc.2001.1365 1:CAS:528:DC%2BD3MXjtlSlu70%3D Sun Y, Zhang J, Zhang JQ, et al.: Renin expression at sites of repair in the infarcted rat heart. J Mol Cell Cardiol 2001, 33:995–1003.
7. 7. RN Re 1999 The nature of intracrine peptide hormone action Hypertension 34 534 528 10523322 1:CAS:528:DyaK1MXntFOitLo%3D Re RN: The nature of intracrine peptide hormone action. Hypertension 1999, 34:534–528.
8. 8. VJ Dzau 2001 Tissue angiotensin and pathology of vascular disease: a unifying hypothesis Hypertension 37 1047 1052 11304501 1:CAS:528:DC%2BD3MXjtFejt70%3D Dzau VJ: Tissue angiotensin and pathology of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047–1052.
9. 9. AHJ Danser JP Kats van PJJ Admirall 1994 Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis Hypertension 24 37 48 8021006 1:CAS:528:DyaK2cXlt1Kjtrc%3D Danser AHJ, van KatsJP, Admirall PJJ, et al.: Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension 1994, 24:37–48.
10. 10. C Delcayre JS Silvestre A Garnier 2000 Cardiac aldosterone production and ventricular remodeling Kidney Int 57 1346 1351 10760065 10.1046/j.1523-1755.2000.00973.x 1:CAS:528:DC%2BD3cXjtVOrtr4%3D Delcayre C, Silvestre JS, Garnier A, et al.: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346–1351.
11. 11. S Fujiyama H Matsubara Y Nozawa 2001 Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated receptor transactivation Circ Res 88 22 29 11139469 1:CAS:528:DC%2BD3MXosVOjsw%3D%3D Fujiyama S, Matsubara H, Nozawa Y, et al.: Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated receptor transactivation. Circ Res 2001, 88:22–29.
12. 12. WC Mello De 2001 Cardiac arrhythmias: the possible role of the renin-angiotensin system J Mol Med 79 103 108 11357932 10.1007/s001090100195 De MelloWC: Cardiac arrhythmias: the possible role of the renin-angiotensin system. J Mol Med 2001, 79:103–108.
13. 13. JR Sowers M Epstein ED Frohlich 2001 Diabetes, hypertension, and cardiovascular disease Hypertension 37 1053 1059 11304502 1:CAS:528:DC%2BD3MXjtFejt7g%3D Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease. Hypertension 2001, 37:1053–1059.